IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jan 17, 2019

Keywords

ClinConnect Summary

This clinical trial is focused on understanding inflammatory bowel diseases (IBD), specifically Crohn's disease and ulcerative colitis. Researchers are trying to identify specific markers in the body that can help predict how these diseases will progress and how patients will respond to certain treatments, known as biotherapies. By finding these markers, doctors hope to improve care for patients with IBD in the future.

To participate in the trial, individuals need to be at least 18 years old and have a confirmed diagnosis of either Crohn's disease or ulcerative colitis. They should also weigh at least 45 kg and be part of the Social Security system. Unfortunately, people with uncertain forms of colitis, those pregnant or breastfeeding, and individuals under 18 or unable to give consent cannot take part. If eligible, participants can expect to contribute to important research that could change how IBD is treated, helping future patients manage their condition more effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age\>=18 years
• • Patients with an established diagnosis of CD or UC (clinical, biological, radiological, endoscopic or histologic criteria)
• • Patients \>=45 kg
• • Affiliated member of the Social Security system
• Exclusion Criteria:
• • Patients with an undetermined colitis
• • Patients with a non established diagnosis of CD
• • Women of childbearing age without a method of contraception
• • Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code
• • Pregnant women, breastfeeding women
• • -- Age \< 18 years
• • Persons under legal protection
• • Person who does not have the capacity to consent
• • Persons under the age of 18 years who are deprived of their liberty by decision of a judicial or administrative authority (articles L. 3212-1 and L. 3213-1).